華潤三九(000999.SZ):1季度CHC業務核心品類中感冒用藥增速快於預期
格隆匯5月31日丨華潤三九(000999.SZ)召開現場會議、電話會議,就“Q1 CHC 業務的表現?”
公司回覆稱,23年一季度感冒藥品類受到補庫存和甲流高發帶動,總體進展良好,業務中佔比較高。兒科感冒藥、皮膚用藥、大健康等業務增長較好。以999理洫王牌血塞通軟膠囊為主的聖火業務一季度也取得較快增長。總體來看,1季度CHC業務核心品類中感冒用藥增速快於預期,其他品類表現符合預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.